InFocus Clinical Research

Wonderful to see Nanoscope Therapeutics Inc. CMO Samuel B Barone present at Eyecelerator this year. Proud to have been a part of their incredible journey with MCO-010 so far.

🎉 Exciting news from our partner, Aviceda Therapeutics! They have successfully completed enrollment for their Phase 2b SIGLEC study, assessing the safety and efficacy of AVD-104 for Geographic Atrophy secondary to AMD. 👏 We’re proud to be an integral part of this groundbreaking research, supporting their mission to bring innovative solutions to patients in need. 🤝 Stay tuned for more updates as we continue to make strides together in advancing retinal therapies! #ClinicalResearch #RetinaResearch #retinastudies #clinicaltrials #ophthalmology https://lnkd.in/eazDTCuJ

🌟 Proud Moment for InFocus Clinical Research! 🌟 We are thrilled to announce that InFocus Clinical Research has been ranked #724 on the 2024 Inc. 5000 list! This achievement is a testament to our team’s dedication, innovation, and unwavering commitment to advancing retina clinical trials. A huge thank you to our incredible team, partners, and clients for making this possible. We’re excited to continue pushing boundaries and making a difference in the world of ophthalmology. https://lnkd.in/eEc6rw_f. #Inc5000 #TeamInFocus #ClinicalResearch #RetinaTrials #Innovation

Congratulations to the Nanoscope Therapeutics Inc. team including Samarendra Mohanty,PhD, Subrata Batabyal, PhD, Ananta Laxmi Ayyagari Ph.D and Naj Sharif, PhD, DSC, on their just-published research article in The Journal of Gene Medicine (https://lnkd.in/ggwpPwid) . The article (https://lnkd.in/gAtFiZT6) details how research aimed to determine the ocular and systemic safety of MCO-010 in adult Beagle dogs following intravitreal (IVT) injection. In the study, MCO-010 demonstrated a favorable safety profile when administered to the eyes of adult Beagle dogs. This study established the No Observed Adverse Effect Level for MCO-010 and guided selection of doses for human clinical trials.   Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. 100-week data from the RESTORE Phase 2b/3 multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772) was recently presented by Dr. Michael Singer at ASRS – American Society of Retina Specialists Meeting in Stockholm. The company has also completed the Phase 2 STARLIGHT trial of MCO-010 therapy in patients with Stargardt disease (NCT05417126 ). MCO-010 has received FDA fast-track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt disease. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophies secondary to AMD. For more information about Nanoscope Therapeutics, visit our website: nanostherapeutics.com   #Genetherapy #retinitispigmentosa #stargardt # geographic atrophy #optogenetics  

There's still time to stop by and say hi to the InFocus team at booth 1342! There might just be a surprise waiting for you in the InFocus Case 👀 #ARVO2024 #Retina #CRO #ophthalmology

Yesterday in Seattle, Dr. Samarendra Mohanty made a presentation on Mutation-Agnostic Vision Restoration in Patients with Retinal Degenerative and participated in a panel discussion on regenerative medicine as part of Ophthalmology Innovation Source Retina Innovation Summit. It was a great opportunity to reconnect with colleagues and meet new people who are working in this important area of research. Today (Sunday 5/5) team Nanoscope Therapeutics Inc. takes part in the opening of #ARVO24. Stop by to meet our leadership team at our booth #4620. We look forward to saying hello as we all kick off a busy week. Monday 5/6, the first of 6 ARVO presentations featuring our MCO-010 optogenetic therapy for retinitis pigmentosa begin with one by Dr. Allen Ho where he will present 12-month results from our Phase 2b/3 RESTORE clinical trial. Details for all presentations are below and on our website: nanostherapeutics.com Longitudinal BCVA analysis of low- or high-dose MCO-010 mutation agnostic optogenetic therapy for retinitis pigmentosa: 12-month results from a Phase 2b/3 randomized, sham-controlled, patient- and assessor-masked clinical trial (RESTORE) Presentation Number: 2137 -  Paper Session May 6, 2024. -- 4:15 – 4:30 p.m. PT 612 - Seattle Convention Center - Arch Building Presenter: Allen Ho, MD, Chief Medical Advisor Test-retest Agreement of the Freiburg Visual Acuity Test in Ultra-low Vision Poster Number: A0223 Type: Poster Session May 7, 2024 -- 1:15 – 3:00 p.m. PT Exhibit Hall - Seattle Convention Center Presenter: Samuel B Barone, MD, CMO Longitudinal BCVA Analysis of Patients with Stargardt Disease and Macular Degeneration Treated With MCO-010, a Mutation-Agnostic Optogenetic Therapy: 48-Week Results From a Phase 2a Clinical Trial (STARLIGHT) Poster Number: B0094 May 8, 2024 --  2:15 – 4:00 p.m. PT Exhibit Hall - Seattle Convention Center Presenter: Vinit B. Mahajan, MD, PhD, Professor of Ophthalmology, Stanford University Multi-characteristic opsin gene therapy attenuates retinal degeneration and restores vision in mouse models of retinitis pigmentosa Abstract/Poster Number: B0293 May 8, 2024 --  2:15 – 4:00 p.m. PT Exhibit Hall - Seattle Convention Center Presenter: Subrata Batabyal, PhD, Director, Non-Clinical Development Characterization of a Broadband Ambient Light Activatable Multi-Characteristic Opsin Supporting its Superior Performance in Restoring Vision Poster Number: B0924 Session Date: May 9, 2024 -- 8:00 – 9:45 a.m. PT Exhibit Hall - Seattle Convention Center Presenter: Samarendra Mohanty, PhD, President and CSO In Vivo Efficacy of a Novel Multi-Characteristic Opsin (MCO-010) in a Mouse Model of Leber Congenital Amaurosis Poster Number: B0942 May 9, 2024 -- 8:00 – 9:45 a.m. PT Exhibit Hall - Seattle Convention Center Presenter: Naj Sharif, PhD, DSC, VP of Global Research and Development Sulagna Bhattacharya #ophthalmology #retina #clinicaltrials

Nanoscope Therapeutics Inc. President Samarendra Mohanty discussing regulatory opportunities in the development of gene therapies at the Retinal Cell and Gene Therapy Innovation Summit in Seattle

Inspiring work by Annexin Pharmaceuticals AB (publ) presented by CEO Anders Haegerstrand - a trial we are proud to be a part of...

Stop by to chat with the InFocus Clinical Research team at ARVO Seattle! Be sure to visit our booth 1342 and learn more! #ARVO2024 #InFocusClinicalResearch #Ophthalmology #Retina

Nanoscope Therapeutics Inc. is excited to announce positive top-line results after the completion of the 2-year Phase 2b RESTORE trial of MCO-010 for Retinitis Pigmentosa. Highlights of results include: - MCO-010 achieved its primary and key secondary endpoints with statistical significance and no serious adverse events - Data from the Phase 2b RESTORE trial demonstrate clinically meaningful vision improvement in legally blind individuals with progressive and permanent neurodegeneration of the retina - RESTORE is the first randomized, controlled trial of a mutation-agnostic gene therapy for a genetic disease - Nanoscope anticipates submitting a Biologics License Application to the U.S. FDA in the second half of 2024 The Phase 2b RESTORE trial represents the only randomized controlled trial in retinal degenerative disease to demonstrate improvement beyond the clinically important BCVA > 0.3 LogMAR threshold in a statistically significant manner. These results are consistent with what has been previously observed in the earlier Phase 1/2a open-label study. Improvements in visual function persisted or increased following week 52 in the study, demonstrating the durable effect of a single intravitreal injection of MCO-010. The high-dose MCO-010 (1.2E11gc/eye) is planned to be the commercial dose. Additional data from this clinical trial will be presented in a series of scientific meetings in the coming months, beginning with a presentation at the Annual Scientific Meeting of the Association for Research in Vision and Ophthalmology (ARVO) on May 6, 2024, in Seattle, Washington, by Allen Ho, MD, Director of Retina Research and Co-Director of the Retina Service at Wills Eye Hospital. For more information, including a summary of top-line efficacy results:  https://lnkd.in/gJcq2Kdk #clinicaltrials #retinitispigmentosa #genetherapy #biotechnology #cureblindness Sulagna Bhattacharya Samarendra Mohanty David Boyer, MD Arshad M. Khanani Glenn Sblendorio